Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3432309 | American Journal of Obstetrics and Gynecology | 2016 | 8 Pages |
Abstract
Solitomab induces robust immunologic responses in vitro that result in increased T-cell activation, proliferation, production of cytokines, and direct killing of tumor cells. These findings suggest that solitomab may represent a novel, potentially effective agent for the treatment of recurrent/metastatic and/or chemo-resistant uterine serous carcinoma-overexpressing epithelial cell adhesion molecule.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Stefania PhD, Jonathan MD, Diana P. MD, Carlton L. MD, Salvatore MD, Emiliano PhD, Elena MS, Federica MS, Francesca MD, Elena MD, Dan-Arin MD, Masoud MD, Peter E. MD, Alessandro D. MD,